Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 3/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461796 | 0.93 | DHODH (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL23461794 | 0.93 | DHODH (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL23461810 | 0.93 | DHODH (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL23461003 | 0.91 | CXCR2 (0.42) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL23461001 | 0.91 | CXCR2 (0.42) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL25549061 | 0.90 | CXCR2 (0.39) | TRPV1CXCR2GCGRGPR132PTGDR2 | |
| SCHEMBL23460963 | 0.88 | CXCR2 (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL38147040 | 0.88 | CXCR2 (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL23460959 | 0.88 | CXCR2 (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 | |
| SCHEMBL25560463 | 0.88 | CXCR2 (0.39) | DHODHPTPN1CYP3A4TRPV1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | DHODH 1523/4885PTPN1 1876/4885CYP3A4 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.